SEC CRD #802-116739
Catalys Pacific Charter People Creations Perspectives Governance Contact Us Investor Login EN EN JP CHART THE UNCHARTED CREATING INNOVATION FOR PATIENTS New Current See all June 15, 2026 Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study Read More Featured Creations See all IPO Mineralys A Targeted Approach for the Control of Hypertension Acquired Renalys Catalyst to access novel therapies for Asian patients with renal disease Pathalys A New Path for Patients with Chronic Kidney Disease Catalyzing Transpacific Partnership The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an on-the-ground , local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors. Meet the Team Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.” Nobuo Hanai, PhD Our Charter Learn more
Minami Aoyama
MANAGING DIRECTOR AND CHIEF COMPLIANCE OFFICER
📞 81-50-1744-2996
🔒 Sign up for free to view key contact information
Sign up free →This profile has not yet been verified by the firm. Information may be incomplete or outdated. Claim this profile to take control of your listing.
Location
TOKYO
Claim this profile to complete your information, set investment criteria, and start receiving curated deal flow from sponsors on DEALITHIC.